Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (002932.SZ)
CNY 18.76
(-0.74%)
CNY 18.76
(-0.74%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 7.38 Billion CNY | -19.63% |
| 2022 | 9.19 Billion CNY | 168.97% |
| 2021 | 3.41 Billion CNY | 139.52% |
| 2020 | 1.42 Billion CNY | 123.46% |
| 2019 | 638.42 Million CNY | 3.45% |
| 2018 | 617.14 Million CNY | 140.57% |
| 2017 | 256.53 Million CNY | 30.13% |
| 2016 | 197.14 Million CNY | 47.17% |
| 2015 | 133.95 Million CNY | 119.56% |
| 2014 | 61.01 Million CNY | 156.45% |
| 2013 | 23.79 Million CNY | 410.85% |
| 2012 | 4.65 Million CNY | 137.91% |
| 2011 | 1.95 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 6.82 Billion CNY | -1.49% |
| 2024 Q1 | 7.24 Billion CNY | -1.97% |
| 2024 Q2 | 6.93 Billion CNY | -4.25% |
| 2023 Q2 | 7.97 Billion CNY | -10.08% |
| 2023 FY | 7.38 Billion CNY | -19.63% |
| 2023 Q1 | 8.87 Billion CNY | -3.49% |
| 2023 Q4 | 7.38 Billion CNY | -4.19% |
| 2023 Q3 | 7.7 Billion CNY | -3.34% |
| 2022 FY | 9.19 Billion CNY | 168.97% |
| 2022 Q4 | 9.19 Billion CNY | 22.82% |
| 2022 Q3 | 7.48 Billion CNY | 15.5% |
| 2022 Q2 | 6.47 Billion CNY | 22.8% |
| 2022 Q1 | 5.27 Billion CNY | 54.4% |
| 2021 FY | 3.41 Billion CNY | 139.52% |
| 2021 Q4 | 3.41 Billion CNY | 48.92% |
| 2021 Q3 | 2.29 Billion CNY | 14.71% |
| 2021 Q1 | 1.86 Billion CNY | 30.97% |
| 2021 Q2 | 2 Billion CNY | 7.06% |
| 2020 Q3 | 1.24 Billion CNY | 19.79% |
| 2020 FY | 1.42 Billion CNY | 123.46% |
| 2020 Q1 | 748.87 Million CNY | 17.3% |
| 2020 Q2 | 1.04 Billion CNY | 39.25% |
| 2020 Q4 | 1.42 Billion CNY | 14.21% |
| 2019 Q1 | 630.99 Million CNY | 2.24% |
| 2019 Q2 | 640.09 Million CNY | 1.44% |
| 2019 Q4 | 638.42 Million CNY | -0.33% |
| 2019 Q3 | 640.54 Million CNY | 0.07% |
| 2019 FY | 638.42 Million CNY | 3.45% |
| 2018 Q3 | 592.31 Million CNY | 97.73% |
| 2018 Q1 | 267.2 Million CNY | 4.16% |
| 2018 Q2 | 299.55 Million CNY | 12.1% |
| 2018 FY | 617.14 Million CNY | 140.57% |
| 2018 Q4 | 617.14 Million CNY | 4.19% |
| 2017 Q4 | 256.53 Million CNY | 0.0% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q2 | 223.24 Million CNY | 0.0% |
| 2017 FY | 256.53 Million CNY | 30.13% |
| 2016 Q4 | 197.14 Million CNY | 0.0% |
| 2016 FY | 197.14 Million CNY | 47.17% |
| 2016 Q3 | 197.14 Million CNY | 21.54% |
| 2016 Q2 | 162.21 Million CNY | 0.0% |
| 2016 Q1 | 162.21 Million CNY | 21.09% |
| 2015 Q3 | 133.95 Million CNY | 26.78% |
| 2015 Q2 | 105.66 Million CNY | 0.0% |
| 2015 Q4 | 133.95 Million CNY | 0.0% |
| 2015 FY | 133.95 Million CNY | 119.56% |
| 2015 Q1 | 105.66 Million CNY | 73.18% |
| 2014 Q2 | 51.34 Million CNY | 0.0% |
| 2014 FY | 61.01 Million CNY | 156.45% |
| 2014 Q3 | 61.01 Million CNY | 18.84% |
| 2014 Q1 | 51.34 Million CNY | 115.8% |
| 2014 Q4 | 61.01 Million CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 Q3 | 23.79 Million CNY | 0.0% |
| 2013 Q4 | 23.79 Million CNY | 0.0% |
| 2013 FY | 23.79 Million CNY | 410.85% |
| 2012 FY | 4.65 Million CNY | 137.91% |
| 2011 FY | 1.95 Million CNY | 0.0% |